MCQs Quiz

The Regulatory system of Canada, led by Health Canada, ensures drug safety, efficacy and quality through a framework of laws, policies and scientific review. B. Pharm students must understand drug approval pathways (New Drug Submission, Abbreviated NDS, Notice of Compliance), clinical trial applications, licensing, post-market surveillance, pharmacovigilance, Good Manufacturing Practices and the Drug Identification Number … Read more

Understanding the regulatory system of Japan, especially the role of the Pharmaceuticals and Medical Devices Agency (PMDA), is essential for B. Pharm students. This concise guide covers Japan’s drug approval pathway, clinical trial notification, dossier submission (eCTD/CTD), pharmacovigilance, post-marketing surveillance, GMP/GCP/GLP expectations, Sakigake and orphan drug pathways, risk management plans, regulatory inspections, and marketing authorization … Read more

Introduction: The regulatory framework of Australia (TGA) covers laws, guidelines, and processes that ensure the safety, quality and efficacy of therapeutic goods. For B. Pharm students, understanding TGA roles, the Australian Register of Therapeutic Goods (ARTG), AUST R vs AUST L listings, Good Manufacturing Practice (GMP), clinical trial schemes, post‑marketing surveillance, advertising rules, scheduling (Poisons … Read more

Introduction: The European Medicines Agency (EMA) is the central EU body that coordinates scientific evaluation, supervision and safety monitoring of human medicines. For B.Pharm students, understanding EMA functions and approvals is essential: committees like CHMP, PRAC, COMP and PDCO set scientific standards; systems such as the centralized procedure, conditional authorisation, orphan designation and PRIME accelerate … Read more

Understanding the organization structure of the US FDA and application types is essential for B.Pharm students focusing on regulatory affairs and drug development. This concise guide explains FDA centers (CDER, CBER, CDRH, CVM), key offices, regulatory pathways and common application types such as IND, NDA, ANDA, BLA, 505(b)(2), 510(k) and PMA. It also covers review … Read more

Overview of regulatory authorities in India (CDSCO) MCQs With Answer Understanding the Central Drugs Standard Control Organization (CDSCO) is essential for B. Pharm students preparing for careers in pharmaceuticals, regulatory affairs, and clinical research. This introduction explains CDSCO’s role under the Drugs and Cosmetics Act, core functions such as approval of new drugs, medical device … Read more

Post-approval changes to NDA or ANDA are modifications made to an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) involving manufacturing, formulation, labeling, CMC, analytical methods, packaging, supplier or manufacturing site. Understanding regulatory pathways—such as prior-approval supplements (PAS), changes-being-effected (CBE), and annual reports—comparability protocols, SUPAC guidances, stability and bioequivalence requirements, and risk-based … Read more

The Abbreviated New Drug Application (ANDA) process is a core regulatory pathway for generic drug approval. This introduction explains key concepts B. Pharm students must know: ANDA submission under 505(j), bioequivalence (AUC/Cmax), Reference Listed Drug (RLD), FDA Orange Book, Paragraph IV patent challenges, 180-day exclusivity, BCS-based biowaivers, Drug Master Files (DMFs), cGMP, and labeling requirements. … Read more

Introduction The New Drug Application (NDA) approval process is a critical regulatory pathway that B. Pharm students must understand to support drug development, regulatory submission, and market authorization. This topic covers NDA structure, Chemistry, Manufacturing and Controls (CMC), preclinical and clinical data requirements, Good Manufacturing Practices (GMP) inspections, FDA review timelines (PDUFA), safety and pharmacovigilance, … Read more

Introduction Understanding Timelines for IND submission and review is essential for B. Pharm students preparing for roles in clinical development and regulatory affairs. This concise guide covers key timelines—initial 30-day FDA safety review, PDUFA goals, priority vs standard review, clinical holds, pre-IND meetings, IND amendments, safety reporting deadlines, eCTD/CTD filing structure, CMC and preclinical data … Read more